Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121567278> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2121567278 endingPage "3292" @default.
- W2121567278 startingPage "3287" @default.
- W2121567278 abstract "Activity in the cancer vaccine sector has quadrupled in the last decade. A number of therapeutic cancer vaccines are reaching the market. The huge number of clinical trials in progress is expected to undergo evaluation shortly. Whole cell tumor vaccines or gene-modified whole cells are being intensively tested in clinical trials. However, the specificity of the product makes the drug development process, including clinical trials, a considerable challenge. Their complex nature, standardization of manufacturing, and characterization often pose problems. Accordingly, to develop a well characterized controlled vaccine, more than a few factors need to be established. The final cell vaccine formulation must be characterized for product identity, purity, impurities, sterility, potency, cell viability, and total cell number. Therapeutic cancer vaccines show different clinical characteristics than cytotoxic anticancer agents. Unfortunately, the rules of clinical trial design for active immunotherapy have been adapted from the designs for examination of cancer chemotherapy. Accordingly, many research groups and clinical consortia have postulated modifications and unifications of existing clinical trial designs. A clinical development model has suggested that cancer vaccines be investigated in 2 categories of clinical trials: proof-of- principle and efficacy. Moreover, it is becoming clear that no drug demonstrates anticancer activity in all patients. Thus, intensive studies have been performed to seek specific biomarkers which could help stratify patients who are likely to respond to a particular treatment. This presents a big challenge beyond the analysis of the immune system status necessary to assess the effects of active immunotherapy." @default.
- W2121567278 created "2016-06-24" @default.
- W2121567278 creator A5005706056 @default.
- W2121567278 creator A5031394337 @default.
- W2121567278 date "2010-10-01" @default.
- W2121567278 modified "2023-09-26" @default.
- W2121567278 title "Gene-Modified Cellular Vaccines: Technologic Aspects and Clinical Problems" @default.
- W2121567278 cites W1488215556 @default.
- W2121567278 cites W1831933605 @default.
- W2121567278 cites W1872420254 @default.
- W2121567278 cites W1973917219 @default.
- W2121567278 cites W1974498683 @default.
- W2121567278 cites W1983097329 @default.
- W2121567278 cites W1985124264 @default.
- W2121567278 cites W1985803217 @default.
- W2121567278 cites W1986731760 @default.
- W2121567278 cites W2028697741 @default.
- W2121567278 cites W2039849856 @default.
- W2121567278 cites W2056165918 @default.
- W2121567278 cites W2059204380 @default.
- W2121567278 cites W2062803993 @default.
- W2121567278 cites W2076163094 @default.
- W2121567278 cites W2100158834 @default.
- W2121567278 cites W2129449089 @default.
- W2121567278 cites W2245362616 @default.
- W2121567278 cites W2402588640 @default.
- W2121567278 cites W1774980384 @default.
- W2121567278 doi "https://doi.org/10.1016/j.transproceed.2010.07.028" @default.
- W2121567278 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20970673" @default.
- W2121567278 hasPublicationYear "2010" @default.
- W2121567278 type Work @default.
- W2121567278 sameAs 2121567278 @default.
- W2121567278 citedByCount "9" @default.
- W2121567278 countsByYear W21215672782012 @default.
- W2121567278 countsByYear W21215672782015 @default.
- W2121567278 countsByYear W21215672782018 @default.
- W2121567278 countsByYear W21215672782019 @default.
- W2121567278 crossrefType "journal-article" @default.
- W2121567278 hasAuthorship W2121567278A5005706056 @default.
- W2121567278 hasAuthorship W2121567278A5031394337 @default.
- W2121567278 hasConcept C121608353 @default.
- W2121567278 hasConcept C126322002 @default.
- W2121567278 hasConcept C177713679 @default.
- W2121567278 hasConcept C203014093 @default.
- W2121567278 hasConcept C2777701055 @default.
- W2121567278 hasConcept C2778378633 @default.
- W2121567278 hasConcept C2780035454 @default.
- W2121567278 hasConcept C535046627 @default.
- W2121567278 hasConcept C64903051 @default.
- W2121567278 hasConcept C71924100 @default.
- W2121567278 hasConcept C98274493 @default.
- W2121567278 hasConceptScore W2121567278C121608353 @default.
- W2121567278 hasConceptScore W2121567278C126322002 @default.
- W2121567278 hasConceptScore W2121567278C177713679 @default.
- W2121567278 hasConceptScore W2121567278C203014093 @default.
- W2121567278 hasConceptScore W2121567278C2777701055 @default.
- W2121567278 hasConceptScore W2121567278C2778378633 @default.
- W2121567278 hasConceptScore W2121567278C2780035454 @default.
- W2121567278 hasConceptScore W2121567278C535046627 @default.
- W2121567278 hasConceptScore W2121567278C64903051 @default.
- W2121567278 hasConceptScore W2121567278C71924100 @default.
- W2121567278 hasConceptScore W2121567278C98274493 @default.
- W2121567278 hasIssue "8" @default.
- W2121567278 hasLocation W21215672781 @default.
- W2121567278 hasLocation W21215672782 @default.
- W2121567278 hasOpenAccess W2121567278 @default.
- W2121567278 hasPrimaryLocation W21215672781 @default.
- W2121567278 hasRelatedWork W2050391874 @default.
- W2121567278 hasRelatedWork W2088663266 @default.
- W2121567278 hasRelatedWork W2372770165 @default.
- W2121567278 hasRelatedWork W2385157319 @default.
- W2121567278 hasRelatedWork W2388075619 @default.
- W2121567278 hasRelatedWork W2613158600 @default.
- W2121567278 hasRelatedWork W2794003560 @default.
- W2121567278 hasRelatedWork W3024269876 @default.
- W2121567278 hasRelatedWork W3049299998 @default.
- W2121567278 hasRelatedWork W4206732464 @default.
- W2121567278 hasVolume "42" @default.
- W2121567278 isParatext "false" @default.
- W2121567278 isRetracted "false" @default.
- W2121567278 magId "2121567278" @default.
- W2121567278 workType "article" @default.